Health and Fitness Health and Fitness
Tue, December 7, 2010
[ Tue, Dec 07th 2010 ] - Market Wire
Pro-Pharmaceuticals Expands Patent Coverage to Australia
[ Tue, Dec 07th 2010 ] - Market Wire
Les donn©es de trois pr©sentations ©valuant le .. mide chez les patients atteints de my©lome multi
[ Tue, Dec 07th 2010 ] - Market Wire
Orthovita Receives FDA Clearance for Vitossa" Bioactive Foam-2X Bone Graft Substitute
[ Tue, Dec 07th 2010 ] - Market Wire
Affymax to Present at the Deutsche Bank 2010 BioFEST Conference
[ Tue, Dec 07th 2010 ] - Market Wire
Auf der Jahrestagung der US-amerikanischen Hmatol .. die klinischen Daten aus zwei Phase II-Studien z
[ Tue, Dec 07th 2010 ] - Market Wire
Exactech Announces Resolution of Government Investigation
[ Tue, Dec 07th 2010 ] - Market Wire
Wright Medical Group, Inc. Announces Initial Release of the PRO-TOEa" VO Hammertoe Fixation System
[ Tue, Dec 07th 2010 ] - Market Wire
Medtronic, Boston Scientific, St. Jude Medical, ZOLL Medical and Abiomed
[ Tue, Dec 07th 2010 ] - Market Wire
N. Anthony Coles, M.D. Named to LabCorp® Board of Directors
[ Tue, Dec 07th 2010 ] - Market Wire
ActiveHealth Management to Deliver Innovative NuV .. Nutritional Scoring System Through Health Website
[ Tue, Dec 07th 2010 ] - Market Wire
Pfizer, Merck, Amazon, eBay and Netflix
[ Tue, Dec 07th 2010 ] - Market Wire
La?Intergroupe Francophone du My©lome (IFM) a © .. de de phase III (IFM 2005 02), le traitement cont
[ Tue, Dec 07th 2010 ] - Market Wire
valuation, dans le cadre da?une ©tude de phase I .. , du traitement continu avec REVLIMID® de patien
[ Tue, Dec 07th 2010 ] - Market Wire
Il trattamento continuo con REVLIMID® per i pazi .. lo in seguito al trapianto autologo di cellule st
[ Tue, Dec 07th 2010 ] - Market Wire
CytRxa?s INNO-206 Safely Delivers High-Dose Doxor .. Human Tumors in Animal Model of Multiple Myeloma
[ Tue, Dec 07th 2010 ] - Market Wire
Pr©sentation l'ASH des donn©es cliniques de deu .. 'administration de REVLIMID® en association avec
[ Tue, Dec 07th 2010 ] - Market Wire
Geron Corporation Announces the Pricing of Its Public Offering of Common Stock
[ Tue, Dec 07th 2010 ] - Market Wire
La Jolla Pharmaceutical Company Announces Appoint .. nt of Dr. Bertrand C. Liang to Board of Directors
[ Tue, Dec 07th 2010 ] - Market Wire
Presentation at American Society of Hematology An .. ing Unfolded Protein Response is Promising Treatm
[ Tue, Dec 07th 2010 ] - Market Wire
Observational Study Demonstrates No Greater Incid .. Myeloid Leukemia with REVLIMID® in Patients with
[ Tue, Dec 07th 2010 ] - Market Wire
L'analyse r©trospective des donn©es cliniques d .. r le REVLIMID®(MDS-004) signale une am©lioratio
[ Tue, Dec 07th 2010 ] - Market Wire
Ex-post-Analyse der klinischen Daten von REVLIMID .. ergibt, dass sich die berlebensrate von Patienten
[ Tue, Dec 07th 2010 ] - Market Wire
Retrospectieve analyse van klinische gegevens uit .. LIMID (MDS-004) laat belangrijke verbetering zien
[ Tue, Dec 07th 2010 ] - Market Wire
Targacept to Present at 2010 Deutsche Bank BioFEST
[ Tue, Dec 07th 2010 ] - Market Wire
Data from Three Presentations Evaluating Clinical .. reviously Treated Multiple Myeloma Presented at A
[ Tue, Dec 07th 2010 ] - Market Wire
REVLIMID®-Daten von Patienten mit multiplem Myel .. nsraten mit niedrig und hoch dosiertem Dexamethas
[ Tue, Dec 07th 2010 ] - Market Wire
Presentazione all'ASH dei dati derivati da tre pr .. e dei benefici clinici del pomalidomide nel mielo
[ Tue, Dec 07th 2010 ] - Market Wire
Aktualisierte klinische Ergebnisse einer Dauerbeh .. er REVLIMID® zeigen eine statistisch signifikant
[ Tue, Dec 07th 2010 ] - Market Wire
Nouvelles donn©es cliniques d'©valuation de l'I .. ©rence ouverte de phase II portant sur des patien
[ Tue, Dec 07th 2010 ] - Market Wire
Apricus Biosciences introduceert educatieve filmp .. ijk goedgekeurde medicijn Vitaros tegen erectiele

Apricus Biosciences introduceert educatieve filmpjes gericht op zijn recentelijk goedgekeurde medicijn Vitaros tegen erectiele


Published on 2010-12-07 09:31:36 - Market Wire
  Print publication without navigation


SAN DIEGO--([ BUSINESS WIRE ])--Apricus Biosciences, Inc. (Nasdaq:APRI), uit San Diego, maakt vandaag bekend dat dr. Bassam Damaj, Ph.D., voorzitter, president en CEO van het bedrijf, online te zien is in educatieve filmpjes die zijn gericht op het recentelijk in november 2010 goedgekeurde medicijn tegen erectiele dysfunctie Vitaros. De filmpjes kunnen worden bekeken vanaf de website van het bedrijf. Ze zijn bedoeld om een antwoord te bieden op veel gestelde vragen over het nieuwe medicijn, dat de eerste goedgekeurde plaatselijke behandeling is op het westelijk halfrond.

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal welke als enige juridische geldigheid beoogt.

Contributing Sources